<DOC>
	<DOCNO>NCT00474773</DOCNO>
	<brief_summary>This study evaluate benefit continue celecoxib six week total knee arthroplasty recovery . This randomized , double blind study group approximately 130 primary total knee patient . All patient receive celecoxib throughout hospitalization per current minimally invasive total knee arthroplasty protocol . At time hospital discharge , participate patient randomly place either celecoxib 200mg twice day placebo twice day . This study determine continue use celecoxib six week total knee arthroplasty hospitalization decrease narcotic consumption , improve knee range motion , improve ambulatory ability , improve patient satisfaction patient receive celecoxib acute hospitalization .</brief_summary>
	<brief_title>Evaluation Post Hospital Administration Celecoxib Following Minimally Invasive Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Celecoxib</mesh_term>
	<criteria>undergone minimally invasive total knee select surgeon voluntarily enrol independent community ambulators patient discharge directly home celecoxib allergy intolerence Renal insufficiency ( define serum creatine level &gt; 1.5 mg/dL BUN level &gt; 22mg/dL History bleed gastic duodenal ulceration New York Heart Association Class III IV Congestive Heart Failure Previous myocardial infarction cerebralvascular event Severe inflammatory bowel disease Known coagulation abnormality hepatic disease Chronic coumadin administration Refusal primary cardiac physician</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>